BGPT: Paper Review: Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases

Explore by Goal

Quick Explanation Copied

Beyond DNA sensing reframes cGAS/STING as a context-dependent hub linking cytosolic/self-DNA (often mtDNA/extranuclear chromatin) to type I IFN, NF-κB, autophagy and inflammatory programs across autoimmunity, cancer, and metabolic disease—while emphasizing that chronic or tissue-specific STING output can flip between protective vs pathogenic roles, complicating therapeutic targeting.

Long Explanation

Paper: “Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases”

Publication: 2023-06-24 • DOI: 10.1007/s12272-023-01452-3

Core claim type

Narrative review • no new primary datasets; synthesizes mechanistic + preclinical + clinical-development evidence.

Bias check: interpret disease/cell-type effects as contextual and model-dependent (review itself stresses pro- vs antitumor flip and cautions about loss-of-cGAS/STING effects).

1) Visual: disease-topic coverage map (from the review’s own taxonomy)

Count is how many disease sections the review explicitly discusses (not an effect-size).

Evidence basis: these modules are extracted from the review’s heading structure and subsections covering autoimmunity, metabolic/liver, kidney, lung, cancer, and cardiovascular/neurologic disease examples.

2) Visual: mechanism backbone (cGAS→cGAMP→STING→TBK1/IRF3 & NF-κB)

Logic chain (as presented)

cGAS activation by cytosolic dsDNA (including exogenous microbial DNA and endogenous DNA such as mitochondrial DNA/extranuclear chromatin).
cGAMP synthesis: DNA engagement induces cGAS catalytic pocket rearrangements leading to 2′3′-cGAMP.
STING activation on ER: cGAMP binding triggers conformational rearrangements and STING oligomerization, then trafficking (ER→ERGIC→Golgi), enabling downstream signaling.
TBK1→IRF3 and NF-κB outputs: TBK1 phosphorylates STING and/or recruits IRF3, promoting type I interferon (IFN) gene transcription; canonical NF-κB activation also contributes to inflammatory cytokines/chemokines.

Note on rigor: this is a mechanism backbone; the review repeatedly emphasizes that downstream consequences differ by cell type, DNA source, and duration/chronicity.

3) Visual: ‘double-edged’ outputs (beneficial vs harmful) by domain

This bar chart is a qualitative categorization derived from the review’s described disease-directional claims (pro/anti). It is not a quantitative meta-analysis.

The review explicitly stresses that STING/cGAS can be protective or pathogenic depending on cancer context and that loss-of-pathway can sometimes worsen autoinflammation.

4) Mechanistic ‘expansion’: beyond DNA sensing into cell biology + signaling integration

Traffic & compartmentalization matter: STING activation depends on ER→Golgi pathway and requires TBK1/IRF3 axis; many consequences map onto where STING goes and what it recruits.
Endogenous DNA sources: the review repeatedly links disease to cytosolic self-DNA—especially mitochondrial DNA released due to cellular damage—consistent with foundational cGAS biology.
Signal output is coupled to broader cellular programs (not only IFN): e.g., autophagy-related steps have been proposed as part of the pathway’s physiological roles.

5) Skeptical critique: what the review does well vs where evidence is weaker

Strengths (evidence-based)

Mechanistic anchor points (cGAS→cGAMP→STING→TBK1/IRF3 and NF-κB) are consistent with structural and signaling literature, including cGAS catalytic mechanism and STING activation structure.
Disease coverage breadth: autoimmunity/autoinflammation, metabolic/liver, kidney, lung fibrosis/inflammation, and multiple cancer contexts are systematically cataloged (helpful for hypothesis generation).

Potential blind spots / limitations

Narrative review selection bias: because this is not presented as a systematic meta-analysis, the set of highlighted studies may overrepresent “canonical” mechanisms and omit contradictory negative/neutral datasets.
Contextual pro/anti-tumor roles require careful causal framing: the review acknowledges that chronic activation can yield immunosuppressive tumor microenvironments and can also promote metastasis in some systems—yet many cited data points likely come from different model types and conditions, which limits direct generalization.
Therapeutic translation isn’t resolved by association alone: the review lists many modulators, but the mismatch between target biology (cell-type/compartment) and clinical pharmacology (distribution, dosing, patient stratification) remains a major uncertainty in the field. (The review calls for careful design and cautions about lack of pathway.)

6) Evidence examples supporting the review’s framing (with skepticism labels)

Selected mechanistic anchors (not exhaustive)

Self-DNA can cause autoimmunity via cGAS/STING: cGAS is required for lethal autoimmune disease in Trex1-deficient mouse models (supporting the idea that endogenous DNA↔cGAS is causally inflammatory in some settings).
Cell death / compartment damage can link to STING: STING trafficking can couple to autophagy as a primordial function of the cGAS pathway (supports ‘beyond sensing’ expansion into cell-biological programs).
Inflammation vs immune evasion in cancer: review highlights both anti-tumor IFN/T-cell priming and pro-metastatic/noncanonical NF-κB or immunosuppressive tumor microenvironment scenarios. A primary mechanistic metastasis/cytosolic DNA link is consistent with broader literature on STING/cytosolic DNA in cancer programs.

7) Translational landscape critique: modulators catalog vs mechanism-specific risk

What the review emphasizes

cGAS inhibitors target catalytic site and DNA binding interfaces (e.g., G-class compounds, RU family, PF fragments, antimalarial-like DNA-binding blockade strategies).
STING inhibitors include agents binding the cyclic dinucleotide pocket and/or covalently targeting transmembrane-domain residues; the review also covers TBK1 inhibition strategies.
STING activators include a large pipeline of CDNs/analogues, nanoformulations, and delivery platforms for antitumor immunity (but clinical efficacy has been mixed for some first-wave agents).

Skeptical note: the review’s breadth is a strength for navigation, but it also means individual evidence strands are often not weighed with effect-size rigor, and species differences (e.g., ligand compatibility) and delivery constraints can dominate translational outcomes (example supported by the ASA404 human non-binding issue).

8) What would most disprove/reshape the review’s central framing?

If carefully controlled genetics/interventions in specific human-relevant tissues show that STING/cGAS pathway output does not drive the labeled disease phenotypes (e.g., loss-of-cGAS/STING in human cohorts fails to stratify disease or fails to match pathway activation signatures), then the disease mapping would weaken. (The review notes caution and context dependence, implicitly acknowledging this risk.)
If the causal direction flips in well-replicated interventional models (e.g., STING activation reliably protective across all disease contexts, or reliable harmful-only behavior disappears), then the ‘double-edged hub’ concept would need refinement.

Author reviews (open deep-dives in BGPT)

Feedback:

Updated: April 17, 2026